Infinity Bio has introduced a new antibody profiling platform using MIPSA technology.
This platform is set to enhance research in immunology, virology, autoimmunity, and allergy by offering depth in immune system analysis.
The MIPSA technology harnesses recent advancements in high-throughput DNA sequencing and DNA synthesis, enabling the creation and analysis of the most comprehensive panels of immune targets currently available.
Infinity Bio has developed MIPSA to examine the vast array of antibodies present in blood or other fluids, providing a detailed understanding of individual immune responses.
The technology represents a significant advancement in antibody profiling, achieving breadth and resolution in mapping the molecular targets of immune responses.
The company’s current catalogue of antigen panels includes VirSIGHT, HuSIGHT, and AllerSIGHT. They combine full-length protein and peptide libraries.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Infinity Bio CEO Caroline Popper said: “As a leader in antibody profiling, we aim to surpass the limits of previous technologies by offering best-in-class infrastructure and processes in a truly state-of-the-art purpose-built laboratory to manage large sample and data sets, provide cutting-edge analyses and return insights into disease aetiology.
“Our services support academic and pharmaceutical researchers, including large cohort studies, with great potential to enhance clinical trial outcomes and therapy selection.”
The antibody profiling services from the company will be instrumental in various applications, including cohort studies to discover disease mechanisms, triggers, and modifiers.
In clinical trials, the platform will enhance patient phenotypic characterisation and stratification based on immune responses.
For vaccine development, the platform will link antibody responses to vaccine efficacy and identify unforeseen liabilities.
Additionally, it will uncover biomarkers for infectious and autoimmune diseases through unbiased patient antibody profiling and precisely define the binding profiles of clinical or reagent-grade monoclonal antibodies, including off-target reactivities.
